About this trial
Sickle cell disease (SCD) is a prevalent inherited blood disorder characterized by vaso-occlusive crises (VOCs), which lead to severe pain and complications. Despite hydration being a cornerstone of VOC management, the optimal fluid strategy remains uncertain. This study evaluates restrictive versus liberal fluid management strategies in patients with acute VOC.
This multi-center, open-label, non-inferiority RCT will enroll patients with SCD presenting with acute VOC. Participants will be randomized to either a restrictive or liberal intravenous fluid management protocol. Primary outcome is pain score reduction. Secondary outcomes include time to pain resolution, ED length of stay, hospital admission rate, cumulative opioid dose, adverse events (incidence of fluid overload, pulmonary congestion), acute chest syndrome, incidence of acute kidney injury, revisit rates within 72 hours of ED discharge, need for intensive care or high-dependency unit admission, need for additional interventions, and 28 days overall mortality. Data will be analyzed using intention-to-treat principles.
We hypothesize that a restrictive fluid strategy will achieve non-inferior pain control compared to a liberal strategy, while minimizing fluid-related complications. This study will provide evidence to inform clinical guidelines for fluid management in SCD patients experiencing VOCs.
Eligibility criteria
Qualifiers
Patients >18 years old with a confirmed diagnosis of SCD.
Presenting with a VOC.
NPRS >5
Willingness to participate and provide informed consent.
Disqualifiers
Patient requiring specialized IVF management as per the treating physician discretion.
Patients with congestive heart failure, and /or acute or chronic symptomatic systolic heart failure
Patients with ESRD on chronic dialysis
Patients with signs of shock (low SBP <100 or MAP < 65) and signs of hypo perfusion
Trial design
Treatments tested in this trial
- Sodium Chloride (NaCl) 0.9 %
- Sodium Chloride (NaCl) 0.9 %